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A B S T R A C T
 
Background: Chronic graft-versus-host disease is a serious complication of allogeneic 
hematopoietic cell transplantation, and the mouth is one of the affected sites. 
Objective: The aim of this study was to evaluate the oral features of this disease after 
hematopoietic cell transplantation.
Methods: This was a cross-sectional multicenter study that enrolled patients submitted to 
transplantation. Oral evaluations used the National Institutes of Health criteria, salivary 
flow rates, and the range of mouth opening. Pain and xerostomia were evaluated through a 
visual analogue scale. Patients were divided into two groups based on the transplantation 
time (up to one year and more than one year).
Results: Of the 57 evaluated recipients, 44 had chronic graft-versus-host disease: ten (22.72%) 
in the group with less than one year after transplantation, and 34 (77.27%) in the group with 
more than one year after transplantation. Lichenoid/hyperkeratotic plaques, erythematous 
lesions, xerostomia, and hyposalivation were the most commonly reported oral features. 
Lichenoid/hyperkeratotic plaques were significantly more common in patients within the 
first year after the transplant. The labial mucosa was affected more in the first year. No 
significant changes occurred in the frequency of xerostomia, hyposalivation, and reduced 
mouth opening regarding time after transplantation.
Conclusion: Oral chronic graft-versus-host disease lesions were identified early in the course 
of the disease. The changes observed in salivary gland function and in the range of mouth 
opening were not correlated with the time after transplantation.
© 2014 Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular. 
All rights reserved. 
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Introduction
Allogeneic hematopoietic cell transplantation (HCT) is 
associated with early and late oral complications. Most of these 
complications are related to graft-versus-host disease (GVHD) 
and may cause transitory and/or permanent sequelae. Many 
studies have reported oral manifestations of chronic GVHD 
(cGVHD),1-3 but to the authors’ knowledge, only one study has 
addressed the temporal outcomes of some of these features.4 
Most studies focus on specific oral alterations of cGVHD, and 
have not used the National Institutes of Health (NIH) criteria 
to evaluate the oral features.
cGVHD affects from 50% to 80% of the adult patients who 
undergo HCT, regardless of prophylaxis and donor-patient 
matching techniques.2
Oral manifestations can be the first signs of cGVHD, 
and might be considered a disease marker.3,5 These oral 
manifestations are observed in the majority of cases of 
cGVHD,2,5-7 and are considered an important cause of 
morbidity and loss of quality of life in long-term survivors.5
According to the NIH Consensus Criteria for GVHD, the 
disease is currently diagnosed by its clinical manifestations 
and no longer according to time post-transplantation.8 The 
clinical manifestations of cGVHD are classified as diagnostic, 
distinctive, or common clinical features. The finding of a 
‘diagnostic’ feature of cGVHD establishes the condition without 
further testing. In the oral cavity, these features include lichen 
planus-like lesions, hyperkeratotic plaques, and restriction of 
mouth opening due to skin sclerosis. ‘Distinctive’ features are 
likely to support the diagnosis of cGVHD; however, they are 
not enough to establish the diagnosis. The oral ‘distinctive’ 
features include xerostomia, mucoceles, mucosal atrophy, 
pseudomembranes, and ulcers. ‘Common’ features of cGVHD 
refer to the manifestations found in both acute GVHD and 
cGVHD, which include gingivitis, mucositis, erythema, and 
pain.8
Some clinical changes of oral cGVHD such as vasculitis-
like features or a telangiectatic appearance of the mucosa, 
inflammation, and loss of the stippling of the attached gingiva 
may represent early alterations of oral cGVHD, even though 
they are not considered in the NIH criteria.2 Erosive lesions 
are observed in the most severe forms of cGVHD, and are 
followed by pain, which may interfere in oral hygiene and 
food ingestion.9 Xerostomia generally causes discomfort, but 
hyposalivation, that is, reduced salivary flow rates (SFR), which 
have more serious consequences, have not been included in 
the NIH criteria.10-12 
Temporal features of systemic cGVHD have previously 
been addressed. However, although oral cGVHD has been 
analyzed in many publications,1-3 data regarding the temporal 
relationship of oral features is lacking. The present study aimed 
to perform a cross-sectional evaluation of the oral features of 
cGVHD according to the time after HCT.
Methods
This was a cross-sectional multicenter study conducted in two 
hospitals in Brazil: Hospital Universitário Clementino Fraga 
Filho (HUCFF) of the Universidade Federal do Rio de Janeiro 
(UFRJ) and the Center for Hematology and Hemotherapy of 
the Universidade Estadual de Campinas, from January of 2008 
to January of 2011. Adult patients who underwent HCT for 
hematological conditions were included. All patients signed an 
informed consent. This study was approved by the institution’s 
review board and conducted in accordance with the Helsinki 
Declaration as revised in 2008.
Demographic and clinical characteristics were assessed 
from medical records. After the transplantation, oral 
evaluations were performed by a trained dentist. The oral exam 
was performed using frontal light-emitting diode illumination, 
with the patient sitting on a chair.
Oral features were classified according to NIH criteria as 
diagnostic, distinctive, and common features.8 These features 
referred to any changes related to oral signs and symptoms 
(mucosal lesions, perception of changes in salivary flow rate 
and moisture, changes in sensitivity, and reduction of mouth 
opening). Oral lesions were defined as morphological changes 
of the oral mucosa.
The severity of oral symptoms was scored according to the 
NIH criteria:8 no symptoms (0); mild symptoms with disease 
signs not limiting the oral intake (1); moderate symptoms with 
disease signs, with partial limitation of oral intake (2); and 
severe symptoms with disease signs and major limitation of 
oral intake (3). Moreover, the patients graded oral sensitivity 
through a visual analogue scale (VAS) graduated from 0 (no 
sensitivity) to 10 (worst possible pain).13,14 Positive sensitivity 
was recorded when patients reported symptoms greater than 
0 on the VAS.
Resting SFR were used to assess salivary function under 
standard conditions.15 Saliva samples were collected between 
9:00 a.m and 11:30 a.m.16 Participants were asked not to eat 
until the exam was performed. Patients were instructed to 
spit the accumulated saliva periodically into a disposable 
cup for five minutes. They were instructed not to eat nor 
swallow during the exam.16 The liquid part of the SFR was 
then measured with a disposable syringe. The SFR results were 
determined as milliliters per minute, and reduced SFR was 
defined as < 0.3 mL/min.11
Oral dryness was also evaluated using a VAS graduated 
from 0 (no dryness) to 10 (the worst possible oral dryness). To 
eliminate common causes of dry mouth feeling, xerostomia 
was considered when the patient recorded a score > 2.13
The oral involvement of scleroderma was evaluated using 
a Willis compass to measure the maximum range of mouth 
opening (RMO). The device measured the midline distance 
from the border of the central upper incisors to the border of 
the central lower incisors. Reduced RMO was defined as < 35 
mm.17
In order to analyze the temporal manifestations of cGVHD, 
the patients were separated in two groups: within one year 
post-HCT and over one year post-HCT. In general, cGVHD 
develops from three to 15 months after HCT,1 and the period of 
one year post-HCT has been used in some studies to evaluate 
cGVHD.18,19 The date of the transplant was an accurate datum 
and was available for all patients.
The SPSS© version 13.0 (IBM - Chicago, USA) was used to 
store and analyze data. The differences between groups were 
analyzed with Fisher’s exact test and the Mann-Whitney test 
for the comparison of categorical and continuous variables, 
respectively. The level of significance was set as a p-value < 
0.05.
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Results
Fifty-seven patients who underwent HCT were analyzed; 
27 (47.4%) women and 30 (52.6%) men. The median age was 
43 years, ranging from 18 to 64 years. Among the patients 
submitted to HCT, 68.4% presented oral features. The clinical 
and demographic characteristics of the 57 HCT patients 
are shown in Table 1. The oral features of the HCT patients 
included in the study are listed in Table 2.
Forty-four (77.2%) patients developed cGVHD. Among the 
cGVHD patients, 88.63% presented oral features. This analysis 
was focused primarily on patients with cGVHD, as the majority 
of the HCT recipients developed this condition. Among the 
patients who developed cGVHD, the mouth was the most 
frequently affected site (88.63%), regardless of the different 
stem cell sources (bone marrow: 71.4%; peripheral blood: 
66.7%). The most affected organs were the mouth, skin, liver, 
eyes, and lungs.
The most common oral features observed in cGVHD patients 
were oral lesions (70.45%), xerostomia (56.81%), reduced SFR 
(47.72%), and reduced RMO (31.81%). The most common types 
of oral lesions in cGVHD patients were erythema (54.54%) and 
lichenoid/hyperkeratotic lesions (52.27%). Lichenoid lesions are 
considered a diagnostic feature by the NIH criteria, and were 
observed in all patients that presented oral features within one 
year post-HCT; many patients presented more than one type 
of oral manifestation. The NIH classification and grading of 
the cGVHD patients who presented oral features are listed in 
 
Clinical characteristics
All 
patients
Patients 
with 
cGVHD
Patients 
with 
cGVHD
n = 57 
(100.0%)
n = 13 
(22.80%)
n = 44 
(77.19%)
Gender - n (%)
    Male 30 (52.63) 10 (76.90) 20 (45.50)
    Female 27 (47.36) 3 (23.10) 24 (54.50)
Age
    Median 43 35.00 45.00
    Range 18.00-64.00 19.00-53.00 18.00-
64.00
Underlying disease - n (%)
    Acute lymphocytic  
      leukemia
4 (7.01) - 4 (9.10)
    Acute myelogenous 
      leukemia
18 (31.57) 2 (15.40) 16 (36.40)
    Chronic myelogenous 
      leukemia
22 (38.59) 8 (61.50) 14 (31.80)
    Aplastic anemia 8 (14.03) 3 (23.10) 5 (11.40)
    Myelofibrosis 2 (3.50) - 2 (4.50)
    Hodgkin’s lymphoma 1 (1.75) - 1 (2.30)
    Non-Hodgkin’s lymphoma 1 (1.75) - 1 (2.30)
    Multiple myeloma 1 (1,75) - 1 (2.30)
Conditioning regimen - n (%)
    Bu + Cy 36 (63.15) 8 (61.50) 28 (65.10)
    Bu + Cy + Flu 5 (8.77) - 5 (11.60)
    Others 15 (26.31) 5 (38.50) 10 (23.30)
Donor gender - n (%)
    Male 27 (47.36) 8 (61.50) 19 (43.20)
    Female 30 (52.63) 5 (38.50) 25 (56.80)
Related donor - n (%) 57 (100.00) 13 (100.00) 44 (100.00)
Stem cell source - n (%)
    Bone marrow 23 (40.35) 8 (61.50) 15 (34.10)
    Peripheral blood 34 (59.64) 5 (38.50) 29 (65.90)
Time post-transplantation - (days) 
    Median 921 1476 839.50
     Range 48-4,136 48-3,100 159-4,136
Previous acute GVHD - n (%) 19 (33.33) 4 (33.30) 15 (34.10)
GVHD: graft-versus-host disease; cGVHD: chronic graft-versus-host 
disease; Busulfan: Bu; Cyclophosphamide: Cy; Fludarabine: Flu.
Table 1 - Clinical and demographic characteristics 
of the 57 patients submitted to hematopoietic cell 
transplantation.
 
Features
Patients 
without 
cGVHD
Patients 
with 
cGVHD
 
p-value
n = 13 
(22.80%)
n = 44 
(77.19%)
Oral lesions - n (%)
    Lichenoid/hyperkeratotic - 23 (52.30) < 0.01
    Erythema 1 (7.70) 24 (54.50) 0.03
    Ulcers 1 (7.70) 11 (25.00) NS
    Mucoceles - 8 (18.20) NS
    Atrophy 4 (30.76) 17 (38.60) NS
    Drug-induced gingival 
      hyperplasia
1 (7.70) - NS
Presented sensitivity - n (%) 5 (38.50) 30 (68.20) NS
Oral sensitivity (VAS) 0.02
    Median 0.00 0.60
    Range 0.00-4.80 0.00-8.00
Presented xerostomia - n (%) 3 (23.10) 25 (56.80) 0.05
Xerostomia (VAS) 0.01
    Median 0.30 2.45
    Range 0.00-7.00 0.00-10.00
Presented hyposalivation - n (%) 1 (7.70) 21 (47.70) 0.01
Resting salivary flow rates (mL/min) 0.02
    Median 0.50 0.30
    Range 0.08-0.92 0.00-1.00
Patients with reduced range of  
  mouth opening - n (%)
2 (15.40) 15 (34.10) 0.08
Range of mouth opening (mm) 0.06
    Median 39.00 35.00
    Range 32.00- 
48.00
24.00-
50.00
cGVHD: chronic graft-versus-host disease; HCT: hematopoietic cell 
transplantation; NS: non-significant; VAS: visual analogue scale.
Table 2 - Oral features of the 57 patients submitted to 
hematopoietic cell transplantation.
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Table 3. Data on the characteristics of the oral lesions, salivary 
function, and RMO according to the time post-transplantation 
are listed in Tables 4, 5, and 6, respectively.
There were no differences related to the time of 
transplantation regarding the features of xerostomia, SFR, 
or RMO. Moreover, there was no relationship between 
hyposalivation and gender (p-value = 0.39) or age (p-value = 
0.93). Among the patients who had cGVHD, 54.5% presented 
concomitant xerostomia and sensitivity. Only ten (22.7%) 
patients had concomitant ulcers and sensitivity.
Discussion
This study was relevant due to the evaluation of all oral cGVHD 
features in a standardized manner. Most of the studies on oral 
cGVHD evaluated isolated aspects of the disease. Moreover, the 
present study was one of the first to evaluate these features 
using the NIH criteria. Besides the subjective way that the NIH 
defines these criteria, objective evaluations were performed 
for the signs and symptoms of oral cGVHD. To the best of the 
 
Oral lesions
Less than 
one year 
of HCT
n = 9 
(23.07%)
More than 
one year 
of HCT
n = 30 
(76.92%)
 
p-value
n (%) n (%)
Classification of oral features
    Diagnostic 9 (100.00) 15 (50.00) < 0.01
    Distinctive 7 (77.80) 24 (80.00) NS
    Common 6 (66.70) 20 (66.70) NS
Severity of oral features
    No symptoms 1 (11.10) 9 (30.00) NS
    Mild 3 (33.30) 13 (43.30) NS
    Moderate 5 (55.60) 8 (26.70) NS
Some patients presented more than one kind of oral feature and 
in different oral sites. 
HCT: hematopoietic cell transplantation; NS: non-significant.
Table 3 - Classification and grading of oral features 
of chronic graft-versus-host disease according to the 
National Institutes of Health criteria (n = 39).
 
Lesions
Less than 
one year 
of HCT
More than 
one year 
of HCT
 
p-value
n = 9 
(23.07%)
n = 30 
(76.92%)
Type of oral lesiona - n (%)
    Lichenoid/hyperkeratotic 9 (100.00) 14 (46.70) < 0.01
    Erythema 5 (55.60) 19 (63.30) NS
    Ulcers 3 (33.30) 8 (26.70) NS
    Mucoceles 4 (44.40) 4 (13.30) 0.06
Oral sensitivity - n (%) 7 (77.80) 23 (76.70) NS
Oral sensitivity (VAS) NS
    Median 0.70 0.15
    Range 0.00-1.70 0.00-6.00
Anatomical site of oral lesionsa - n (%)
    Vermillion border 3 (33.30) 8 (26.70) NS
    Labial mucosa 5 (55.60) 5 (16.70) 0.03
    Tongue 8 (88.90) 16 (53.30) NS
    Buccal mucosa 8 (88.90) 18 (60.00) NS
    Palate 5 (55.60) 10 (33.30) NS
    Gingiva 5 (55.60) 21 (70.00) NS
HCT: hematopoietic cell transplant; NS: non-significant; VAS: 
visual analogue scale. 
a Some patients present more than one kind of oral feature and in 
different oral sites.
Table 4 - Early and late characteristics of oral lesions in 
chronic graft-versus-host disease (n = 39). 
 
Salivary flow rate and 
perception
Less than 
one year 
of HCT
More than 
one year 
of HCT
 
p-value
n = 9 
(23.07%)
n = 30 
(76.92%)
Xerostomia - n (%) 7 (77.80) 18 (60.00) NS
Xerostomia (VAS)
    Median 2.10 3.00 NS
    Range 0.00-8.80 0.00-10.00
Hyposalivation - n (%) 6 (66.70) 15 (60.00) NS
Resting salivary flow rate (mL/min)
    Median 0.25 0.27 NS
    Range 0.00-0.36 0.00-0.80
HCT: hematopoietic cell transplant; VAS: visual analogue scale; NS: 
non-significant.
Table 5 - Early and late characteristics of salivary 
function in chronic graft-versus-host (n = 39).
 
Range of mouth opening
Less than 
one year 
of HCT
More than 
one year 
of HCT
 
p-value
n = 9 
(23.07%)
n = 30 
(76.92%)
Patients with reduced range of 
  mouth opening
1 (11.10) 13 (43.30) NS
Range of mouth opening (mm) NS
    Median 39.50 32.50
    Range 33.00-
44.00
24.00-
48.00
HCT: hematopoietic cell transplant; NS: non-significant.
Table 6 - Early and late characteristics of the range of 
mouth opening in chronic graft-versus-host disease  
(n = 39).
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authors’ knowledge, there is no study correlating the frequency 
and the severity of oral cGVHD lesions with the time post-HCT. 
Only one study evaluated the temporal correlation of salivary 
flow and taste changes with time post-HCT, but the authors 
also included patients without GVHD in the analysis.4
In the present study, the frequency of cGVHD was 
consistent with data reported in the literature, even when the 
majority received GVHD prophylaxis to prevent the disease.9 
Among cGVHD patients, the mouth was the most affected site, 
regardless of the time post-HCT. When tracking oral aspects of 
cGVHD patients, it is observed that the morphological changes 
of the existing alterations vary along the course of the disease. 
Considering the temporal differences in oral manifestations of 
cGVHD, the patients in this study were divided into two groups; 
more than and less than one year after HCT.
Diagnostic features were significantly more frequent 
in cGVHD patients in the less than one year group; the 
labial mucosa was more affected in the first year after 
transplantation. In the literature, lichenoid lesions, considered 
a diagnostic feature, have been observed in over 80% of cGVHD 
patients.1 In the present study, nearly half of the cGVHD 
patients presented lichenoid oral lesions/hyperkeratotic 
plaques. However, when the temporal factor was considered, 
cGVHD patients with less than one year post-HCT presented 
significantly more lichenoid lesions/hyperkeratotic plaques. 
This finding suggests the presence of time-related changes 
regarding this type of oral lesion. Healthcare professionals 
should be aware of these lesions as the first oral sign of cGVHD.
Oral pain has been reported as a frequent symptom in 
cGVHD,20 and is generally associated with ulcerations.14 In 
fact, the majority of the cGVHD patients in the present study 
presented mild to moderate symptoms. However, only a 
few patients presented sensitivity related to the oral ulcers. 
Moreover, there were no significant differences in the oral 
symptomatology of cGVHD patients in relation to the time 
post-HCT. No significant temporal differences were observed 
for the other oral signs or symptoms.
Reduced SFR is related to several systemic conditions, such 
as Sjögren’s syndrome, diabetes mellitus, hepatitis C, and some 
immunological diseases, as well as some medications.10 After 
transplantation, late alterations in salivary function are related 
to cGVHD.12,21,22 Severe involvement of the salivary glands 
causes permanent destruction of the salivary parenchyma, 
and oral dryness may be observed.2,21,22 In cGVHD, there 
is a progressive reduction in the production of saliva due to 
parenchymal atrophy of the minor salivary glands.12,21,22 
Apparently, this progressive salivary dysfunction was not 
observed in the cGVHD population of the present study, as there 
were no significant temporal differences observed in SFR. The 
understanding of this finding should be a focus of future studies.
Although older patients are more likely to have 
hyposalivation, the most likely causes are medications and 
disease.23 In the studied population, there were no significant 
differences between the reduced SFR and age.
The feeling of dry mouth does not necessarily correlate to 
signs of hyposalivation.12 In the present study, 9.1% of cGVHD 
patients with xerostomia presented normal SFR. This may be 
explained by the changes in the sialochemistry or by sensory 
alterations.24
There was no correlation between oral mucosa changes and 
salivary dysfunction in the patients with oral cGVHD of the 
present study. This is in agreement with a study that reported 
that salivary gland and oral mucosa involvement are separate 
features of cGVHD.12
Scleroderma is a rare and late manifestation of cGVHD.25 
Sclerodermatous plaques on the lips and in the oral tissues 
may result in the impairment of joint mobility, leading to a 
permanent restriction of mouth opening.26,27 In the present 
study, there were no significant differences in the RMO of the 
cGVHD patients in relation to the time post-HCT.
The frequency of oral alterations in patients who received 
HCTs was high, even among those who did not develop 
cGVHD (61.5%). This figure is higher than the prevalence of 
oral alterations in the Brazilian population (22.0%).28 The oral 
alterations observed in HCT recipients without cGVHD may be 
associated with the treatment for the hematologic condition, 
such as cyclosporine-related gingival hyperplasia.29 The oral 
erythema and ulceration observed in these patients may result 
from injuries that frequently occur in the oral mucosa. The 
four cases of atrophy in patients with no history of cGVHD 
may represent early cases of the disease. Among these four 
patients, only one had less than one year post-transplantation; 
in this case, acute GVHD was considered in the differential 
diagnosis. Oral sensitivity was significantly higher in patients 
with cGVHD, which may be explained by the fact that 
cGVHD patients have more oral features. Xerostomia and 
hyposalivation were also significantly higher in patients who 
developed cGVHD than in other HCT recipients; the mean SFR 
of HCT recipients who did not develop cGVHD was considered 
to be within the normal limits.30 Among the patients who 
did not develop GVHD, there was only one who presented 
hyposalivation and three who presented xerostomia. This 
may be due to the fact that early salivary gland dysfunction 
in post-HCT may be related to toxicity of the conditioning 
regimen.11,13,15
One of the limitations of this study was its sample size. 
Although the study was performed in two hematological 
centers, there were still difficulties in recruiting patients due 
to the fact that, currently, few patients receive HCT. The cross-
sectional analysis may also present some limitation, especially 
because the majority of patients had more than one year of 
post-HCT. Future studies should prospectively evaluate the 
oral features of cGVHD, correlating them to features in other 
organs.
Conclusion
The frequency of oral changes in patients who received HCT 
was high, even for those who did not develop cGVHD. Among 
the patients with cGVHD, the oral diagnostic features of 
lichenoid/hyperkeratotic lesions were more frequently found 
in patients in the early stage of the disease. There were no 
statistically significant differences in the frequency of oral 
mucosal sensitivity, xerostomia, hyposalivation, and RMO in 
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cGVHD patients with less than one year of transplantation 
when compared to those with more than one year post-HCT.
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